GENOMIND, INC.
KING OF PRUSSIA, PA

Based in King of Prussia, PA, Genomind, Inc. stands out as a pioneering firm focused on the intersection of genetic testing and mental health treatment optimization. Known for its innovative spirit, Genomind was honored by the Philadelphia Business Journal as Emerging Company of the Year. The company brings forward The Genecept Assay®, a patented cheek swab test that zeroes in on an individual's unique genetic markers to guide clinicians in crafting highly personalized treatment plans. This test identifies which treatments are likely to be effective or ineffective and highlights those that might lead to adverse effects, ultimately refining therapeutic strategies. The foundations of Genomind were laid by Dr. Ronald I. Dozoretz and Dr. Jay Lombard. At the helm today is CEO Shawn O'Brien along with President Kip Olmstead. The company's advisory board benefits from the expertise of professionals like John Chadwick, reinforcing their strategic direction. Since its establishment in 2015 (Filed Number: F15000002171), Genomind has focused on bridging the gap between genetic data and clinical decision-making, all under a team driven by seasoned experts across various domains such as finance, operations, marketing, and scientific research. Their commitment to equality at work is reflected in their equal opportunity employment policy and drug-free environment, along with competitive benefits for their employees. A key player in advancing precision medicine, Genomind works tirelessly to develop technologies that promote individualized healthcare solutions, integrating genetic insights seamlessly into mental health treatments. As the company expands its reach worldwide, it stays dedicated to transforming how mental health care operates by leveraging advanced genetic information. To explore more about Genomind's role as a trailblazer in psychopharmacology and biomarker testing within psychiatry, their website at genomind.com offers comprehensive insights.